Effects of 4-aminopyridine in patients with multiple sclerosis.
4-Aminopyridine (4-AP) was administered to two groups of patients with multiple sclerosis (MS). The first group consisted of 5 patients with labile visual symptoms, 2 of whom had arcuate scotomata. 4-AP improved visual performance of most patients in this group and reduced the size of scotomata. The second group consisted of 5 patients with the spinal form of MS who were in a stable state; in this group 4-AP had little effect clinically or on tests of visual function.
D015761:4-Aminopyridine; D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000627:therapeutic use*; D004056:Differential Threshold; D005074:Evoked Potentials, Visual / Q000187:drug effects; D006801:Humans; D008027:Light; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D012607:Scotoma / Q000188:drug therapy; D014786:Vision Disorders / Q000188:drug therapy / Q000209:etiology
D000631:Aminopyridines; D015761:4-Aminopyridine